- The FDA has approved Gilead Sciences Inc's GILD Trodelvy (sacituzumab govitecan-hziy) for adult patients with advanced or metastatic breast cancer.
- The approval covers unresectable locally advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
- The approval is based on statistically significant and clinically meaningful progression-free survival and overall survival data from the Phase 3 TROPiCS-02 study.
- Trodelvy is recommended as a Category 1, preferred treatment for metastatic HR+/HER2- breast cancer by the National Comprehensive Cancer Network (NCCN).
- In the TROPiCS-02 study, Trodelvy demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit of 3.2 months versus comparator single-agent chemotherapy.
- Trodelvy also demonstrated a 34% reduction in disease progression or death risk.
- Three times as many people treated with Trodelvy were progression-free at one year versus those treated with chemotherapy.
- In 2022, Trodelvy generated sales of $680 million, 79% Y/Y, reflecting the continued adoption in metastatic triple-negative breast cancer in the U.S. and Europe.
- Price Action: GILD shares are up 4.14% at $84.76 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in